Sánchez MCM

Language: Spanish
References: 9
Page: 105-106
PDF size: 110.84 Kb.

REFERENCES

1. Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022; 387 (7): 631-639. doi: 10.1056/NEJMra1904655.

2. Devic E. Myélite aigue dorso-lombaire avec névrite optique-Autopsie. En: Congres Francais de Médecine (Premiere Session; Lyon, 1894; Procès-Verbaux, Mémoires et Discussions). Lyon, France; Paris, France: Asselin et Houzeau; Louis Savy, 1895. pp. 434-439.

3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364 (9451): 2106-2112.

4. de Seze J, Kremer L, Collongues N. Neuromyelitis optica spectrum disorder (NMOSD): A new concept. Rev Neurol (Paris). 2016; 172 (4-5): 256-262.

5. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016; 79 (5): 775-783.

6. Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021; 96 (2): 59-77.

7. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017; 92 (4): 663-679.

8. Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, et al. Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology. 2018; 91 (17): e1642-e1651.

9. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015; 84 (11): 1165-1173.